Key result
Valsartan matches ACE inhibitors for preventing post-AMI LV dysfunction with ~73% fewer adverse reactions.
Why the study?
Does valsartan prevent left ventricular dysfunction and remodeling as effectively as ACE inhibitors in Japanese patients with acute myocardial infarction?
Population
241 Japanese patients with their first episode of acute myocardial infarction successfully treated by…
Comparison
Valsartan started within 10 days of admission… vs Angiotensin-converting enzyme inhibitor selected…
Design
RCT, Randomly assigned to treatment with valsartan or ACEI
Follow-up
6 months
Authors
Loading...
Supports valsartan preference over ACE inhibitors post-MI for equivalent efficacy and better tolerability; confirms RCT findings in Japanese patients.
RCT (n=241)
Randomly allocated
Yes
Does valsartan prevent left ventricular dysfunction and remodeling as effectively as ACE inhibitors in Japanese patients with acute myocardial infarction?
Absolute Event Rate: 54.9% vs 56.2%
p-value: p=NS
Valsartan is as effective as ACE inhibitors in preventing left ventricular remodeling after acute myocardial infarction in Japanese patients, while offering a significantly better tolerability profile.
Suzuki et al. (2009) conducted an RCT in Acute myocardial infarction (n=241). Valsartan vs. Angiotensin-converting enzyme inhibitors (ACEI) was evaluated on Left ventricular ejection fraction at 6 months (%) (p=NS). Valsartan exhibited similar efficacy to ACE inhibitors in preventing left ventricular dysfunction after acute myocardial infarction, but had a significantly lower incidence of adverse drug reactions (3.3% vs 12.4%, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: